215
Participants
Start Date
July 29, 2013
Primary Completion Date
January 13, 2016
Study Completion Date
February 5, 2019
BMN165 20mg/day
BMN165 20mg/day self-administered daily
BMN165 40mg/day
BMN165 40mg/day self-administered daily
Placebo
Non-drug placebo, self-administered daily
Icahn School of Medicine at Mount Sinai Medical Center, New York
Albany Medical Center, Albany
Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh
St. Christopher's Hospital for Children, Philadelphia
Emory Universty, Department of Human Genetics, Division of Medical Genetics, Atlanta
University of Florida Clinical Research Center, Gainesville
University of South Florida, Tampa
Vanderbilt Children's Hospital, Nashville
University of Louisville, Kosair Charities Pediatric Clinical Research Unit, Louisville
University of Kentucky Medical Center, Lexington
University Hospitals Case Medical Center, Cleveland
Indiana CTSI Clinical Research Center, Indianapolis
Wayne State University Clinical Research Center at the Mott Center, Detroit
Medical College of Wisconsin, Milwaukee
Ann and Robert H Lurie Children's Hospital of Chicago, Chicago
Washington University Center for Applied Research Sciences, St Louis
University of Missouri Health Center, Columbia
University of Nebraska Medical Center, Omaha
University of Oklahoma Health Sciences Center, Oklahoma City
University of Texas Houston Medical School, Houston
Children's Hospital Colorado, Aurora
University of Utah Hospital, Salt Lake City
University of California, San Diego Clinical and Translational Research Institute, La Jolla
UCSF Benioff Children's Hospital Oakland, Oakland
Oregon Health and Science University, Portland
University of Washinton, Seattle
Boston Children's Hospital, Boston
Cooper Health Systems, Camden
Atlantic Health System - Morristown Medical Center, Morristown
Lead Sponsor
BioMarin Pharmaceutical
INDUSTRY